Cantoni, G
Both CagriSema and retatrutide produce gastrointestinal side effects as their most common adverse events nausea, vomiting, diarrhea, and constipation consistent with the GLP-1 receptor agonist component present in both compounds
For people looking to reduce added sugar without dramatically changing taste or texture, this can be a major advantage
Some best practices include using a clean syringe for each dose if your pharmacy provides multiples, wiping the bottle opening with a clean tissue after each use, and never allowing the syringe to touch anything besides the inside of the bottle and the space under your tongue
Flavours that were previously enjoyable may seem less appealing, while certain foods can taste sweeter, saltier, blander, or leave an unusual aftertaste
these will clarify whether GLP-1s truly slow clinical progression in early AD